Serum albumin-adjusted glycated albumin is a better predictor of mortality in diabetic patients with end-stage renal disease on hemodialysis
Authors:
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 30 (5) , 786-789
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysisJournal of Diabetes and its Complications, 2015
- Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysisAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2015
- Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysisClinical Nephrology, 2012
- Glycated Albumin and Risk of Death and Hospitalizations in Diabetic Dialysis PatientsClinical Journal of the American Society of Nephrology, 2011
- Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?Nature Clinical Practice Nephrology, 2008
- Glycated albumin levels predict long‐term survival in diabetic patients undergoing haemodialysisNephrology, 2007
- Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with DiabetesJournal of the American Society of Nephrology, 2007
- Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA)The Journal of Medical Investigation, 2006
- Assessing glycemic control in patients with diabetes and end-stage renal failureAmerican Journal of Kidney Diseases, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003